|
|
|
|
| LEADER |
01201nam a2200241 u 4500 |
| 001 |
EB002002294 |
| 003 |
EBX01000000000000001165195 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Li, Yan
|
| 245 |
0 |
0 |
|a Adalimumab for adult patients with Crohn's disease
|h Elektronische Ressource
|b a review of clinical effectiveness
|c Yan Li, Nina Frey
|
| 260 |
|
|
|a Ottawa, Ont.
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, May 13, 2020
|
| 300 |
|
|
|a 1 PDF file (36 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Frey, Nina
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK563526
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this report is to review and summarize the relevant literature regarding the clinical effectiveness of adalimumab [ADA] versus infliximab [IFX] or vedolizumab [VEDO] (an anti-integrin) in adult patients with Crohn's disease
|